{"id":58833,"date":"2026-03-05T13:34:55","date_gmt":"2026-03-05T05:34:55","guid":{"rendered":"https:\/\/flcube.com\/?p=58833"},"modified":"2026-03-05T13:34:56","modified_gmt":"2026-03-05T05:34:56","slug":"sichuan-biokins-cd33-adc-bl-m11d1-wins-nmpa-approval-expands-into-myelodysplastic-syndromes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58833","title":{"rendered":"Sichuan Biokin&#8217;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes"},"content":{"rendered":"\n<p><strong>Sichuan Biokin Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA:\u202f688506<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>clinical trial application<\/strong> for <strong>BL-M11D1 for Injection<\/strong>, a <strong>CD33\u2011targeting antibody\u2011drug conjugate (ADC)<\/strong>, for <strong>relapsed or refractory myelodysplastic syndromes (r\/r MDS)<\/strong>. The approval expands the <strong>ADC&#8217;s development<\/strong> beyond ongoing <strong>acute myeloid leukemia (AML) trials<\/strong> in <strong>China and the US<\/strong>, leveraging the <strong>same platform technology<\/strong> as the company&#8217;s <strong>approved iza\u2011bren (Izalutinab brengonatcan)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BL-M11D1 for Injection<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>CD33\u2011targeting ADC<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Same as iza\u2011bren (EGFR\u00d7HER3 bispecific ADC)<\/td><\/tr><tr><td><strong>Linker + Payload<\/strong><\/td><td>Shared system with iza\u2011bren<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Relapsed or refractory myelodysplastic syndromes (r\/r MDS)<\/td><\/tr><tr><td><strong>Ongoing Trials<\/strong><\/td><td>Phase Ib (China) + Phase I (US) for r\/r AML<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adc-platform-synergy\">ADC Platform Synergy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Iza\u2011bren<\/strong><\/td><td>EGFR\u00d7HER3<\/td><td>Multiple cancers<\/td><td>Approved (China); Phase III (TNBC)<\/td><\/tr><tr><td><strong>BL-M11D1<\/strong><\/td><td>CD33<\/td><td>r\/r AML, <strong>r\/r MDS (new)<\/strong><\/td><td>Phase I\/ Ib ongoing; MDS trial approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CD33 Target Validation:<\/strong> CD33 is <strong>highly expressed on myeloid malignancies<\/strong> (AML blasts, MDS dysplastic cells); <strong>gemtuzumab ozogamicin (Pfizer)<\/strong> established proof\u2011of\u2011concept, but <strong>BL-M11D1&#8217;s novel linker\u2011payload<\/strong> may offer <strong>improved efficacy and safety<\/strong>.<\/li>\n\n\n\n<li><strong>Platform Leverage:<\/strong> Using the <strong>same ADC platform<\/strong> as <strong>iza\u2011bren<\/strong>\u2014which achieved <strong>positive Phase III data<\/strong>\u2014de\u2011risks <strong>BL-M11D1 development<\/strong> through <strong>validated manufacturing, linker stability, and payload potency<\/strong>.<\/li>\n\n\n\n<li><strong>MDS Market Opportunity:<\/strong> <strong>Relapsed\/refractory MDS<\/strong> has <strong>limited effective therapies<\/strong> beyond <strong>hypomethylating agents<\/strong> (azacitidine, decitabine) and <strong>transfusions<\/strong>; ADCs represent <strong>novel mechanism<\/strong> for <strong>high\u2011risk disease progression<\/strong>.<\/li>\n\n\n\n<li><strong>Dual\u2011Market Strategy:<\/strong> <strong>Simultaneous China + US development<\/strong> (AML) with <strong>MDS expansion in China<\/strong> maximizes <strong>regulatory optionality<\/strong> and <strong>global partnership attractiveness<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>MDS Market Size<\/strong><\/td><td>~\u202f$2\u202fbillion globally; high\u2011risk r\/r MDS represents underserved segment with 6\u201112 month median survival<\/td><\/tr><tr><td><strong>CD33 ADC Competition<\/strong><\/td><td>Gemtuzumab ozogamicin approved for AML; no approved CD33 ADCs for MDS; BL-M11D1 positioned for first\u2011in\u2011class MDS indication<\/td><\/tr><tr><td><strong>Biokin ADC Leadership<\/strong><\/td><td>Iza\u2011bren success establishes Biokin as <strong>China&#8217;s leading ADC developer<\/strong>; BL-M11D1 validates <strong>platform reproducibility<\/strong> across different targets<\/td><\/tr><tr><td><strong>Myeloid Malignancy Pipeline<\/strong><\/td><td>CD33 + EGFR\u00d7HER3 assets create <strong>hematology\u2011oncology franchise<\/strong>; potential for <strong>combination strategies<\/strong> and <strong>sequential therapy approaches<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding MDS Phase I enrollment, AML clinical data readouts, and CD33 target validation in myelodysplastic disease. Actual results may differ due to risks including myelosuppression toxicity, competitive CD33\u2011directed therapies, and manufacturing scale\u2011up for dual\u2011indication supply.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688506_20260305_M4D5.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260305_M4D5.\"><\/object><a id=\"wp-block-file--media-b1af69ce-43d1-4531-a1aa-50bcca42f1cf\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688506_20260305_M4D5.pdf\">688506_20260305_M4D5<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688506_20260305_M4D5.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b1af69ce-43d1-4531-a1aa-50bcca42f1cf\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,62,857],"class_list":["post-58833","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin&#039;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China&#039;s National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33\u2011targeting antibody\u2011drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r\/r MDS). The approval expands the ADC&#039;s development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company&#039;s approved iza\u2011bren (Izalutinab brengonatcan).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58833\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin&#039;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China&#039;s National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33\u2011targeting antibody\u2011drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r\/r MDS). The approval expands the ADC&#039;s development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company&#039;s approved iza\u2011bren (Izalutinab brengonatcan).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58833\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T05:34:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T05:34:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58833#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58833\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin&#8217;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes\",\"datePublished\":\"2026-03-05T05:34:55+00:00\",\"dateModified\":\"2026-03-05T05:34:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58833\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58833#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58833\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58833\",\"name\":\"Sichuan Biokin's CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-05T05:34:55+00:00\",\"dateModified\":\"2026-03-05T05:34:56+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33\u2011targeting antibody\u2011drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r\\\/r MDS). The approval expands the ADC's development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company's approved iza\u2011bren (Izalutinab brengonatcan).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58833#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58833\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58833#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin&#8217;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin's CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33\u2011targeting antibody\u2011drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r\/r MDS). The approval expands the ADC's development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company's approved iza\u2011bren (Izalutinab brengonatcan).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58833","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin's CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33\u2011targeting antibody\u2011drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r\/r MDS). The approval expands the ADC's development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company's approved iza\u2011bren (Izalutinab brengonatcan).","og_url":"https:\/\/flcube.com\/?p=58833","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T05:34:55+00:00","article_modified_time":"2026-03-05T05:34:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58833#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58833"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin&#8217;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes","datePublished":"2026-03-05T05:34:55+00:00","dateModified":"2026-03-05T05:34:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58833"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58833#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58833","url":"https:\/\/flcube.com\/?p=58833","name":"Sichuan Biokin's CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-05T05:34:55+00:00","dateModified":"2026-03-05T05:34:56+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd (SHA:\u202f688506) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33\u2011targeting antibody\u2011drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r\/r MDS). The approval expands the ADC's development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company's approved iza\u2011bren (Izalutinab brengonatcan).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58833#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58833"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58833#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin&#8217;s CD33 ADC BL-M11D1 Wins NMPA Approval \u2013 Expands into Myelodysplastic Syndromes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58833"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58833\/revisions"}],"predecessor-version":[{"id":58835,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58833\/revisions\/58835"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}